NIAID Releases Tuberculosis Research Agenda

Armen Hareyan's picture
Advertisement

Tuberculosis

Advertisement

The National Institute of Allergy and Infectious Diseases released its Agenda for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

While focusing on MDR/XDR TB, many of the research priorities identified in this document also relate to drug-sensitive tuberculosis. The research priorities identified in the agenda build on a foundation of ongoing NIAID-supported TB research, which currently comprises more than 300 research projects worldwide.

Diagnosing, treating and controlling the spread of TB has become increasingly complicated because of the HIV/AIDS co-epidemic and the emergence of MDR and XDR TB, which threatens to set TB control efforts back to the pre-antibiotic era. According to NIAID Director Anthony S. Fauci, M.D., NIAID developed this TB research agenda to address MDR/XDR TB with appropriate urgency, while reaffirming the Institute's commitment to a robust program of research focused on all aspects of TB. NIAID is well prepared to foster the development of new TB diagnostics, drugs and vaccines, but given the realities of MDR/XDR TB, the research agenda outlines those areas that need additional attention to enable public health officials to more effectively combat all forms of tuberculosis, he says. He notes that the agenda is a Web-based

Advertisement